Pharmaceutical Starpharma (ASX:SPL)
today announced impressive data from AstraZeneca published by the World Intellectual Property Organisation.
The patent for Starpharma’s DEP delivery technology with AstraZeneca’s inhibitor is highly effective across a range of cancer types including leukemias.
Starpharma CEO, Dr Jackie Fairley says the combination with blockbuster products shows a strong synergy, also with other leading anti-cancer drugs and that this could represent an important additional benefit for the DEP platform.
Shares in Starpharma (ASX:SPL)
are trading 12.17 per cent higher to $1.29.